Objectives: We sought to determine the overall observed three-year survival rate of women with breast cancer in Basrah, Iraq, and investigate the associated factors.
Methods: Data was collected retrospectively from the Oncology Center registry in Basrah, all newly diagnosed women with breast cancer between 1 January 2013 and 31 December 2014 were included and followed-up until 31 December 2017. We used the Kaplan-Meier method to estimate the overall survival rates. Cox regression analysis was used to investigate the association between survival and prognostic factors.
Results: A total of 605 women who were diagnosed with breast cancer during 2013- 2014 were included in the study, 44.1% had advanced tumor stages (stage III and IV). The overall observed three-year survival rate was 83.3%. Cox regression analysis showed that late stage (stage IV vs. stage I hazard ratio (HR) = 4.65; 95% confidence interval (CI): 3.28-7.81) and grade (poorly vs. well differentiated HR = 4.10; 95% CI: 3.01-6.82) were significantly associated with poor survival.
Conclusions: The overall observed survival rate of women with breast cancer in Basrah was comparable to that reported for developing countries, but it is poorer than that of developed countries. Advanced stage and poorly differentiated tumors were significant predictors of poor survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370891 | PMC |
| http://dx.doi.org/10.5001/omj.2020.66 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting Late Recurrence in Male Estrogen Receptor-Positive Breast Cancer With Clinical Treatment Score Post-5 years: A SEER database analysis of 65,711 cases.
Clin Breast Cancer
December 2024
Comprehensive Breast Health Center, Zhejiang Provincial Hospital of Chinese Medicine, China. Electronic address:
Purpose: Male breast cancer is an understudied disease with unique clinicopathological features. This study aims to evaluate the predictive value of the Clinical Treatment Score post-5 years (CTS5) in estimating late recurrence risk in estrogen receptor-positive (ER+) male breast cancer patients.
Methods: This retrospective study includes 65,711 ER+ early male (n = 611) and female (n = 65,100) breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2010 and 2018.
Risk reducing mastectomy in Norwegian BRCA1/2 carriers.
Eur J Surg Oncol
December 2024
Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Background: Risk reducing mastectomy (RRM) is an option for women with pathogenic germline variants in BRCA1 or BRCA2 (BRCA1/2). This study investigates and compares RRM-uptake among Norwegian BRCA1/2 carriers from 2008 to 2021, temporal trends, and incidence of breast cancer (BC) after surgery.
Methods: BRCA1/2 carriers without prior breast or ovarian cancer, tested at Oslo University Hospital between January 1st 2008 and December 31st 2021 were included in the study.
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer.
ESMO Open
January 2025
Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain. Electronic address:
Background: The infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer has been associated with a reduced risk of distant metastasis. However, the influence of B-cell tumor infiltration on overall patient survival remains unclear.
Materials And Methods: This study explored the relationship between an antitumor immune response, measured by a 14-gene B-cell/immunoglobulin (IGG) signature, and mortality risk in 9638 breast cancer patients across three datasets.
Novel MRI-based Hyper-Fused Radiomics for Predicting Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer.
Acad Radiol
January 2025
Imaging Center, Harbin Medical University Cancer Hospital, Haping Road No.150, Nangang District, Harbin 150081, China (Q-X.C., L-Q.Z., X-Y.W., H-X.Z., J-J.L., M-C.X., H-Y.S., Z-X.K.). Electronic address:
Rationale And Objectives: To propose a novel MRI-based hyper-fused radiomic approach to predict pathologic complete response (pCR) to neoadjuvant therapy (NAT) in breast cancer (BC).
Materials And Methods: Pretreatment dynamic contrast-enhanced (DCE) MRI and ultra-multi-b-value (UMB) diffusion-weighted imaging (DWI) data were acquired in BC patients who received NAT followed by surgery at two centers. Hyper-fused radiomic features (RFs) and conventional RFs were extracted from DCE-MRI or UMB-DWI.
Structural isomers of carene persuade apoptotic cell death by inhibiting cell cycle in breast cancer cells: An in silico and in vitro approach.
Tissue Cell
December 2024
Department of Food Science and Biotechnology, Sejong University, Gwangjin-gu, Seoul, Republic of Korea. Electronic address:
For the first time, our study provides a comprehensive examination of the anti-cancer effects of structural isomers of carene in breast cancer cells, specifically focusing on cell cycle inhibition and the induction of apoptosis. We utilized the hydro-distillation method to extract Piper nigrum seed essential oil (PNS-EO) and identified its bioactive components through gas chromatography-mass spectrometry (GC-MS) analysis. A total of 46 bioactive compounds were isolated via hydro-distillation, identified through GC-MS analysis, and validated by co-injection using GC analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!